Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab
Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab
复制标题
DOI：
10.1167/iovs.16-20855
复制
发表时间：
2017-02-01
影响因子：
4.4
通讯作者：
Fajnkuchen, Franck
中科院分区：
文献类型：
--
作者：
Giocanti-Auregan, Audrey;Hrarat, Linda;Fajnkuchen, Franck
目的.目的：探讨雷珠单抗治疗糖尿病性黄斑水肿（DME）患者后浆液性视网膜脱离（SRD）对功能和解剖结果的影响。本回顾性研究纳入了所有连续接受雷珠单抗治疗的SRD患者。对于每例SRD患者，随机纳入一名基线最佳矫正视力（BCVA）相同的无SRD患者，以调整其基线BCVA。所有患有SRD的患者均纳入第1组（G1），未患有SRD的患者均纳入G2。主要终点是基线和第12个月（M12）之间BCVA的平均变化。次要终点是基线和M12之间的中央视网膜厚度（CRT）的平均变化、注射次数和增加/减少≥ 15个字母的患者比例。共纳入78只眼，每组39只眼。两组的基线BCVA相似（45.2和45.3字母）。基线和M12之间BCVA的平均变化无统计学差异：G1为11 6 12个字母，G2为12 6 13个字母（P = 0. 78）。G1和G2的基线CRT分别为650 6 130 lm和480 6 79 lm。G1组CRT的平均变化为-235 +/- 170 lm，G2组为-130 +/- 96 lm（P = 0.013）。G1和G2患者接受了5.2次和5.5次注射（P = 0.46）。在第1组中，分别有38.5%和2.6%的患者获得和丢失≥ 15个字母，而在G2组中分别有41%（P = 0.1）和5.1%（P = 0.1）。无论是否存在SRD，均观察到相似的BCVA增益。在DME伴SRD患者中通常观察到的较高视力增益可能与较低的基线BCVA相关。
PURPOSE. To assess the effect of serous retinal detachment (SRD) on functional and anatomical outcomes in ranibizumab-treated patients with diabetic macular edema (DME).METHODS. All consecutive ranibizumab-treated patients with SRD were included in this retrospective study. For each patient with SRD, a patient without SRD with the same baseline best-corrected visual acuity (BCVA) was randomly included for adjustment on their baseline BCVA. All patients with SRD were included in group 1 (G1) and those without SRD in G2. The primary endpoint was the mean change in BCVA between baseline and month 12 (M12). Secondary endpoints were the mean change in central retinal thickness (CRT) between baseline and M12, injection number, and proportion of patients who gained/lost >= 15 letters.RESULTS. Seventy-eight eyes were included, 39 in each group. Baseline BCVA was similar in both groups (45.2 and 45.3 letters). Mean change in BCVA between baseline and M12 was not statistically different: 11 6 12 letters in G1 and 12 6 13 letters in G2 (P = 0.78). Baseline CRT was 650 6 130 lm in G1 and 480 6 79 lm in G2. Mean change in CRT was -235 +/- 170 lm in G1 and -130 +/- 96 lm in G2 (P = 0.013). Patients received 5.2 and 5.5 injections in G1 and G2 (P = 0.46). In group 1, 38.5% and 2.6% of patients respectively gained and lost >= 15 letters versus 41% (P = 0.1) and 5.1% (P = 0.1) in G2.CONCLUSIONS. Similar BCVA gains were observed regardless of the presence of SRD. The higher visual gain usually observed in DME with SRD could be associated with a lower baseline BCVA.